Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 191 - 202 |
| Number of pages | 12 |
| Journal | Seminars in Immunology |
| Volume | 26 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2014 |
Cite this
}
Roles of ligands from the TNF superfamily in B cell development, function, and regulation. / Figgett, William Arthur; Vincent, Fabien; Saulep, Damien; Mackay-Fisson, Fabienne.
In: Seminars in Immunology, Vol. 26, No. 3, 2014, p. 191 - 202.Research output: Contribution to journal › Review Article › Research › peer-review
TY - JOUR
T1 - Roles of ligands from the TNF superfamily in B cell development, function, and regulation
AU - Figgett, William Arthur
AU - Vincent, Fabien
AU - Saulep, Damien
AU - Mackay-Fisson, Fabienne
PY - 2014
Y1 - 2014
N2 - TNF ligands are essential to many aspects of normal B cell biology from development in the bone marrow to maturation in the periphery as well as for activation and differentiation into germinal centre, memory or plasma cells. TNF ligands also influence other aspects of B cell biology such as their ability to present antigens or regulate immune responses. Importantly, inadequate regulation of many TNF ligands is associated with B cell disorders including autoimmunity and cancers. As a result, inhibitors of a number of TNF ligands have been tested in the clinic, with some becoming very successful approved treatments alleviating B cell-mediated pathologies.
AB - TNF ligands are essential to many aspects of normal B cell biology from development in the bone marrow to maturation in the periphery as well as for activation and differentiation into germinal centre, memory or plasma cells. TNF ligands also influence other aspects of B cell biology such as their ability to present antigens or regulate immune responses. Importantly, inadequate regulation of many TNF ligands is associated with B cell disorders including autoimmunity and cancers. As a result, inhibitors of a number of TNF ligands have been tested in the clinic, with some becoming very successful approved treatments alleviating B cell-mediated pathologies.
UR - http://www.sciencedirect.com/science/article/pii/S104453231400058X
U2 - 10.1016/j.smim.2014.06.001
DO - 10.1016/j.smim.2014.06.001
M3 - Review Article
VL - 26
SP - 191
EP - 202
JO - Seminars in Immunology
JF - Seminars in Immunology
SN - 1044-5323
IS - 3
ER -